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Abstract
 
Proteins of the nuclear factor of activated T cells (NFAT) family of transcription factors are
critical for lymphocyte activation in the immune system. In particular, NFATs are important
regulators of inducible IL-4 gene expression. Interferon regulatory factor 4 (IRF4) is an immune
system–restricted interferon regulatory factor that is required for lymphocyte activation, but its
molecular functions in the T lineage remain to be elucidated. We demonstrate that IRF4 po-
tently synergizes with NFATc2 to specifically enhance NFATc2-driven transcriptional activa-
tion of the IL-4 promoter. This function is dependent on the physical interaction of IRF4 with
NFATc2. IRF4 synergizes with NFATc2 and the IL-4–inducing transcription factor, c-maf, to
augment IL-4 promoter activity as well as to elicit significant levels of endogenous IL-4 pro-
duction. Furthermore, naïve T helper cells from mice lacking IRF4 are compromised severely
for the production of IL-4 and other Th2 cytokines. The identification of IRF4 as a partner for
NFATc2 in IL-4 gene regulation provides an important molecular function for IRF4 in T
helper cell differentiation.
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Introduction
 
The immune response to foreign antigens is initiated by
signals transmitted from the cell surface to the signaling
network in the cytoplasm and culminates in the nucleus
with the transcription of genes that mediate the effector re-
sponse. Proteins of the nuclear factor of activated T cells
(NFAT)
 
*
 
 family of transcription factors are central to the
transcriptional regulation of several immune-response
genes, including those encoding cytokines and cell-surface
receptors (1). The calcium-regulated NFAT proteins reside
in the cytoplasm within resting cells. After antigenic stimu-
lation, NFATs are dephosphorylated by the phosphatase
calcineurin and are rapidly translocated into the nucleus,
where they interact with other transcription factors to in-
duce target gene expression. When intracellular calcium
levels decline, NFAT proteins are rephosphorylated by spe-
cific kinases and exported back into the cytoplasm. This cy-
cle of activation can be inhibited by the immunosuppressive
drugs cyclosporin A (CsA) and FK506 (1, 2).
The importance of NFAT proteins in the regulation of
IL-4 gene transcription has been well established. Se-
quences within the proximal IL-4 promoter that are spe-
cific for NFAT binding have been identified and shown to
be critical for inducible IL-4 gene expression (3–6). In addi-
tion, a CsA-sensitive enhancer region has been identified
3
 
 
 
 of the IL-4 gene and has been demonstrated to bind
 
NFATc2 in stimulated Th2, but not Th1, cells (7). Evidence
from mice deficient in NFAT family members suggests that
the in vivo role of NFATs in IL-4 transcription is complex
and that NFAT proteins likely regulate IL-4 gene expression
at multiple stages of IL-4 expression within the immune
system. NFATc1 (NFATc, NFAT2)-deficient mice pro-
duce decreased levels of IL-4, whereas mice that lack
NFATc2 (NFATp, NFAT1) exhibit increased IL-4 pro-
duction (8–11). Although T cells lacking both NFATc1
and NFATc2 produce little IL-4, mice doubly deficient in
NFATc2 and NFATc3 (NFAT4) produce extremely ele-
vated levels of IL-4, suggesting a negative regulatory role
for NFATs in IL-4 production; this may not be directly at
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the level of transcription of the IL-4 gene (12). Additional
proteins controlled by NFAT or that modulate NFAT
function may determine the outcome of NFAT-mediated
gene expression.
NFAT proteins are known to engage in protein–protein
interactions in regulating the expression of target genes.
NFATs cooperatively interact with activator protein 1
(AP-1) transcription factors at composite AP-1/NFAT sites
within the IL-4 promoter (6). The NFAT-interacting pro-
tein 45 (NIP45) physically associates with NFATc2 and en-
hances NFAT-driven IL-4 promoter activity (13). NFATc2
also functionally synergizes with the Th2-restricted tran-
scription factor c-maf to greatly enhance IL-4 transcrip-
tional activity (14). We hypothesized that interactions be-
tween NFAT proteins and additional, hitherto unidentified
transcription factors might play a role in IL-4 gene tran-
scription. The presence of putative binding sequences for
interferon regulatory factor (IRF) proteins within the prox-
imal IL-4 promoter, some of which overlap with NFAT
binding sites, led us to investigate whether members of this
family influenced IL-4 transcriptional activity.
IRF4 (PIP, LSIRF, and ICSAT) is a lymphoid- and
myeloid-restricted member of the IRF family of transcrip-
tion factors that binds to interferon sequence response ele-
ments (consensus 
 
AA
 
NN
 
GAAA
 
) present within the pro-
moters of IRF-regulated genes like the type 1 interferons
(15–18). Although IRF4 has weak affinity for ISREs and
represses their function, it is known to participate in gene
activation via interactions with different transcription fac-
tor partners. One such well-characterized complex is
formed by IRF4 and the Ets family member PU.1 on
composite elements present within the immunoglobulin
light chain (Ig
 
 
 
/
 
 
 
) gene enhancers (15, 19). IRF4 is stably
recruited to these enhancer elements via protein–protein
and DNA–protein interactions, and functions synergisti-
cally with PU.1 to regulate Ig light chain gene expression
in B cells (15, 19, 20). IRF4 also enhances DNA binding
by the E2A-encoded gene product E47 and functions syn-
ergistically to activate transcription from the Ig
 
 
 
 3
 
 
 
 en-
hancer (21). Whereas IRF4 has been extensively studied in
B cells, comparatively little is known about the function of
IRF4 in T cells. IRF4 is clearly critical for lymphocyte
function since IRF4-deficient mice exhibit cell intrinsic
defects in both B and T cells (22). Significantly, IRF4 is
rapidly induced in Th cells after activation via the T cell
receptor, suggesting a role for IRF4 in the regulation of
gene expression in Th cells (16, 17). However, no interac-
tion partner for IRF4, involved in T cell effector func-
tions, has been identified to date.
We have uncovered a role for IRF4 in the regulation of
IL-4 gene expression in conjunction with NFATc2. We
demonstrate that IRF4 potently synergizes with NFATc2
to enhance NFATc2-driven activation of the IL-4 pro-
moter and endogenous IL-4 production. This function
is dependent on the physical association of IRF4 and
NFATc2. Furthermore, naïve Th cells lacking IRF4 are
unable to differentiate into IL-4–producing Th2 effector
cells in vitro. Thus, we have identified NFATc2 and IRF4
 
as transcriptional partners that together regulate inducible
IL-4 gene expression upon T cell activation.
 
Materials and Methods
 
Plasmids and Cell Lines.
 
The M12 B cell lymphoma lines and
EL4 thymoma cell lines were maintained in complete medium
containing RPMI 1640 supplemented with 10% FCS (HyClone
Laboratories), 2 mM glutamine, 50 U/ml penicillin, 50 
 
 
 
g/ml
streptomycin, 100 mM Hepes, and 50 
 
 
 
M 
 
 
 
-ME. 293T cells
were maintained in complete DMEM as above. The Flag-
NFATc2 construct was obtained from Jun O. Liu (Massachusetts
Institute of Technology, Cambridge, MA). The HA-IRF8 and
HA-IRF4 expression plasmids and details on the various mutant
IRF4 constructs have been published previously (19, 20). c-maf
and NIP45 expression plasmids have been described previously
(13, 14). The luciferase reporter constructs IL-4-luc, IL-2-luc,
and Egr3-luc have been described previously (3, 23, 24). IRF4
 
 
 
/
 
 
 
mice were obtained from Taconic Laboratories, and C57BL6
mice were used as controls.
 
Transient Transfection Assays and ELISA.
 
M12 cells were
transfected using a 280-V electroporator (975 
 
 
 
F; Bio-Rad Lab-
oratories) using 5 
 
 
 
 10
 
6
 
 cells in 0.4 ml RPMI per transfection us-
ing 2.5 
 
 
 
g reporter plasmid and 5–10 
 
 
 
g expression plasmid or as
indicated in the figure legends to Figs. 1 and 2. Each transfection
was cultured in 5 ml complete medium, luciferase assays were
performed after 24 h, and the luciferase activity in 20% of each
was measured as per instructions (Promega). Values are reported
as fold increases over the luciferase reporter alone. EL4 cells were
transfected as above except using 20% RPMI. 293T cells were
transfected with 2 
 
 
 
g of each expression plasmid by Effectene
transfection reagent (QIAGEN) as per instructions.
Endogenous IL-4 from the supernatant of transfected M12
cells was assayed 72 h after transfection by ELISA as per instruc-
tions (reagents from BD PharMingen).
 
Coimmunoprecipitation Assays and Immunoblotting.
 
Transfected
293T cells from a 10-cm
 
2
 
 petri dish were stimulated with 50 ng/
ml PMA and 1 
 
 
 
M ionomycin for 2 h. Cells were washed in 1
 
 
 
PBS, and were harvested and lysed in 1 ml lysis buffer (50 mM
Tris-HCl, pH 8.0, 0.5% NP-40, 5 mM EDTA, and 50 mM
NaCl) with the addition of protease inhibitor cocktail tablets
(Roche). After lysis at 4
 
 
 
C, lysates were precleared using A/G
beads (Santa Cruz Biotechnology, Inc.) for 1 h at 4
 
 
 
C and incu-
bated with either agarose-conjugated anti-HA antibody (Santa
Cruz Biotechnology, Inc.) or anti-Flag antibody (Sigma-Aldrich)
for 1.5 h. The agarose beads were washed five times in cold lysis
buffer, and the immunoprecipitates were subjected to SDS-PAGE
and transferred onto Nytran membranes. These were probed with
horseradish peroxidase (HRP)–conjugated anti-HA (Santa Cruz
Biotechnology, Inc.) or anti-Flag (Sigma-Aldrich) antibodies.
Day 5 Th1 or Th2 cultures (from BALB/c mice) were stimu-
lated for 24 h with plate-bound anti-CD3. Cells were harvested
and lysed in IP buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl,
0.5% NP-40, 10% glycerol, 0.1 mM EDTA, 0.5 mM DTT, 1
mM sodium vanadate, and 1 mM PMSF plus protease inhibitor
cocktail; Roche). Immunoprecipitations were performed using
1 mg of cell extracts. Extracts were precleared with protein
G–Sepharose (Amersham Pharmacia Biotech) for 30 min followed
by overnight incubation at 4
 
 
 
C with an anti-NFATc2 polyclonal
antibody (Upstate Biotechnology) or preimmune serum and pro-
tein G. Beads were washed five times with IP buffer and with
vortexing. Proteins were eluted in SDS sample buffer, separated
on a 4–20% gradient SDS-PAGE (Bio-Rad Laboratories), and 
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transferred to polyvinylidene difluoride membrane. IRF4 antisera
was conjugated to HRP using EZ-Link activated peroxidase anti-
body labeling kit (Pierce Chemical Co.) as per the manufacturer’s
instructions, except labeled antibody was isolated using a Micro-
con 100 filter device (Millipore) as instructed. Blots were probed
with a 1:1,000 dilution of HRP-conjugated IRF4 antisera in 1%
ovalbumin and developed by chemiluminescence (Amersham
Pharmacia Biotech). Blots were reprobed with a monoclonal
NFATc2 antibody (Santa Cruz Biotechnology, Inc.) followed by
an incubation with a rabbit anti–mouse secondary antibody
(Zymed Laboratories).
 
Cell Culture and Analysis of Cytokine Production.
 
Naïve Th
cells were isolated from lymph nodes of wild-type (C57B6) and
IRF4
 
 
 
/
 
 
 
 mice and sorted to 95–98% purity by FACS (MoFlo;
Becton Dickinson) for CD4
 
 
 
 CD62L
 
high
 
 populations. For Th
differentiation assays in vitro, cells were resuspended at 10
 
6
 
 cells/
ml in complete medium containing RPMI 1640 supplemented
with 10% FCS (HyClone Laboratories), 2 mM glutamine, 50 U/ml
penicillin, 50 
 
 
 
g/ml streptomycin, 100 mM Hepes, and 50 
 
 
 
M
 
 
 
-ME at 37
 
 
 
C in 5% CO
 
2
 
 and stimulated with plate-bound anti-
CD3 (1 
 
 
 
g/ml) plus anti-CD28 (2 
 
 
 
g/ml). Cells were split 1:4
with fresh medium plus 200 U/ml IL-2 on day 3 after primary
stimulation and then rested. On day 7, cells were washed,
counted, and restimulated with 1 
 
 
 
g/ml anti-CD3 at 10
 
6
 
 cells/ml
in complete medium. For Th1-skewing, 2 ng/ml IL-12 and 10
 
 
 
g/ml anti–IL-4 were added to the primary culture. For Th2-
skewing, 10 ng/ml IL-4 and 10 
 
 
 
g/ml anti–IFN-
 
 
 
 and 10 
 
 
 
g/ml
anti–IL-12 were included. Cell-free supernatants were analyzed
for cytokine production by ELISA 24 h after secondary stimula-
tion or by assessing intracellular cytokine production by FACS
analysis as per instructions (BD PharMingen).
 
Results
 
IRF4 Synergizes with NFATc2 to Specifically Enhance
NFAT-mediated Activation of the IL-4 Promoter.
 
We tested
the ability of IRF4 to transactivate the IL-4 promoter, ei-
ther on its own or in conjunction with NFATc2. M12 B
lymphoma cells and EL4 thymoma cells were each trans-
fected with an IL-4 luciferase reporter construct (IL-4-luc;
Fig. 1, a and b, respectively). Cotransfection with NFATc2
increased the luciferase activity of IL-4-luc by 10–15-fold
compared with that of the vector control. IRF4 by itself
did not significantly increase IL-4 promoter activity in ei-
ther cell type, consistent with its known weak DNA-bind-
ing properties. Interestingly, however, IRF4 was able to
synergize with NFATc2 to substantially augment the abil-
ity of NFATc2 to transactivate the IL-4-luc reporter by
 
 
 
100-fold (Fig. 1, a and b).
We next sought to determine whether IRF4 functions
to enhance NFAT-mediated activation of the promoters of
other genes for which NFAT proteins are known to be
critical regulators. The IL-2 proximal promoter contains
well-characterized NFAT-binding sites and NFATc2 has
been shown to transactivate the IL-2 promoter in vitro (1).
The luciferase activity of an IL-2 luciferase reporter con-
struct (IL-2-luc) transfected into M12 cells was increased in
the presence of NFATc2 but was not affected by IRF4
(Fig. 1 c). In addition, cotransfection of both IRF4 and
NFATc2 did not further enhance IL-2-luc activity (Fig. 1
c). The immediate early gene, Egr3, is regulated by
NFATc2 and its promoter contains DNA sequences that
are bound by NFAT proteins (23, 25). The activity of the
Egr3 promoter luciferase construct (Egr3-luc) was in-
creased by overexpression of NFATc2, however, IRF4 did
not modulate this transactivation (Fig. 1 d). Thus, the tran-
scriptional synergy between IRF4 and NFATc2 is not gen-
eralizable to other NFAT-regulated genes such as IL-2 and
Egr3 but has particular relevance to IL-4 gene transcrip-
tion. Furthermore, this is not due to the binding of IRF4
to NFAT recognition sites within the IL-4 promoter since
IRF4 did not transactivate a luciferase reporter construct
containing three tandem NFAT consensus sequences, nor
did it increase NFAT-driven transactivation of the reporter
(Fig. 1 e).
 
IRF4 Physically Associates with NFATc2. Functional and
Physical Interaction between NFATc2 and IRF4 Does Not Ex-
tend to IRF8.
 
To assess whether the functional interaction
between IRF4 and NFATc2 was the consequence of a
physical association between the two proteins, we per-
formed coimmunoprecipitation assays using IRF4 fused
to the hemagglutinin (HA) epitope (HA-IRF4) and Flag-
tagged NFATc2 (Flag-NFATc2). The two proteins were
ectopically coexpressed in 293T cells and total protein ly-
sates prepared after stimulation with PMA and ionomycin.
Immunoprecipitation of HA-IRF4 using anti-HA antibody
resulted in the coimmunoprecipitation of Flag-NFATc2 as
detected by immunoblotting with anti-Flag antibodies (Fig.
2 a). The association of IRF4 and NFATc2 was corrobo-
rated by the reverse coimmunoprecipitation experiment
using anti-Flag antibody to immunoprecipitate NFATc2
and anti-HA to detect the associated HA-IRF4 by Western
blot (Fig. 2 b). Thus, the potent enhancement of IL-4 pro-
moter activity seen in T and B cell lines is reflected by the
protein–protein interaction between IRF4 and NFATc2
within cells.
To establish the physiological significance of this interac-
tion, we performed coimmunoprecipitation assays using
primary CD4
 
 
 
 Th cells. Protein levels of IRF4 were deter-
mined to be induced strongly within 24 h after restimula-
tion of differentiated Th1- or Th2-cytokine producing cells
in vitro (unpublished data). Therefore, we chose this time
point to assess endogenous association of NFATc2 and
IRF4 within primary Th1 and Th2 subsets (see Materials
and Methods). Precleared Th1 and Th2 cell lysates were
subjected to immunoprecipitation using control preim-
mune sera (Fig. 2 c, lane 1) or anti-NFATc2 antibody (Fig.
2 c, lanes 2 and 3) and immunoblotted using HRP-conju-
gated IRF4 antisera to detect the associated IRF4 protein
(Fig. 2 c). Blots were reprobed with anti-NFATc2 antibody
to detect the levels of NFATc2 present in the immunopre-
cipitates. Thus endogenous NFATc2 and IRF4 proteins as-
sociate with each other within primary Th cells.
To further study the specificity of the IRF4–NFATc2
interaction, we asked whether IRF8 (ICSBP), the IRF
family member with the greatest homology to IRF4,
would associate with NFATc2. Interestingly, IRF8 does
not interact with NFATc2 under identical conditions (Fig. 
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2 d). We went on to ask whether IRF8 was capable of syn-
ergizing with NFATc2 to activate IL-4 transcriptional ac-
tivity. Ectopic expression of IRF8 alone, as well as in com-
bination with NFATc2, failed to modulate NFAT-driven
induction of IL-4-luc promoter activity in M12 cell lines
(Fig. 2 e). Thus, the functional synergy between IRF4 and
NFATc2, leading to an enhanced IL-4 transcriptional ac-
tivity, is not applicable to the closely related IRF protein
IRF8. This is consistent with the inability of IRF8 to phys-
ically interact with NFATc2.
 
Domains within IRF4 Required for Interaction and Transcrip-
tional Synergy with NFATc2.
 
To identify the regions
within the IRF4 protein that are important for its interac-
tion with NFATc2, we performed coimmunoprecipitation
experiments using a series of HA-tagged mutant IRF4
constructs (Fig. 3 a) each coexpressed in 293T cells in con-
junction with Flag-NFATc2. Compared with the full-
length IRF4 (1–450), COOH-terminal deletion mutants
1–439 and 1–419 exhibited reduced interactions with
NFATc2, whereas deleting 40 amino acids in the COOH
terminus of IRF4 (1–410) completely abolished interac-
tion with NFATc2. Amino acid residues 399–413 within
this COOH-terminal region of IRF4 were predicted to
form an 
 
 
 
-helix that was shown to be critical for its inter-
action with PU.1 (20). Full-length IRF4 with the putative
 
 
 
-helix deleted (
 
 
 
 H) also was unable to interact with
NFATc2, indicating the importance of the 
 
 
 
-helix in
IRF4-NFATc2 protein–protein interactions. In addition,
regions of IRF4 between amino acids 150 and 340 of the
protein likely contribute to the association of IRF4 and
NFATc2 as seen by the weak associations between
NFATc2 and each of the internal deletion mutants of
Figure 1. IRF4 synergizes with NFATc2 to enhance
NFATc2-driven IL-4 transcriptional activity but does not
regulate the IL-2 and Egr3 promoters. M12 B lymphoma
cells (a) and EL4 thymoma cells (b) were transiently trans-
fected with the IL-4 luciferase reporter and cotransfected
with the indicated microgram amounts of IRF4 and/or
NFATc2 expression plasmids. M12 cells were transiently
transfected with (c) IL-2 luciferase reporter or (d) Egr3 lu-
ciferase reporter and cotransfected with control vectors (15
 g), NFATc2 (15  g) or IRF4 plasmids (15  g) individu-
ally or together (7.5  g each). (e) M12 cells transfected
with the 3 NFAT luciferase reporter and the indicated
microgram amounts of IRF4 and/or NFATc2. All results
represent the mean of three to five independent experi-
ments. Luciferase activity is reported as a fold increase rela-
tive to reporter alone   SEM. 
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IRF4, 
 
 
 
 200–260, 
 
 
 
 260–340, 
 
 
 
 150–260, 
 
 
 
 150–340
(Fig. 3 a).
We next sought to assess whether the domains within
IRF4 that were important for its interaction with NFATc2
also were critical for its transcriptional synergy with
NFATc2 on the IL-4 promoter. Various IRF4 mutants
were transiently transfected into M12 cells along with
NFATc2 and their effect on IL-4 promoter activity assessed
(Fig. 3 b). Consistent with its essential role in interacting
with NFATc2, the COOH-terminal region of IRF4 also is
important for transcriptional synergy. However, residues
419–439 may play an inhibitory role in transcriptional acti-
vation of the IL-4 promoter since the mutant 1–419 exhib-
ited greater transcriptional activity in conjunction with
NFATc2 compared with that of IRF4 mutants 1–439 and
1–410 (Fig. 3 b). The putative interaction helix (399–413)
is critical for the ability of IRF4 to synergize with NFATc2
since deleting the 
 
 
 
-helix (
 
 
 
 H) severely abrogated IL-4
promoter activity. In addition, amino acid residues be-
tween 150 and 340 also appear to be important for tran-
scriptional synergy, as evidenced by the inability of internal
deletion mutants 
 
 
 
 200–260, 
 
 
 
 260–340, 
 
 
 
 150–260, and
 
 
 
 150–340 to synergize with NFATc2 and transactivate
the IL-4 promoter (Fig. 3 b). Thus, the COOH-terminal
region and the amino acids 150–340 of the IRF4 protein
are important for transcriptional synergy as well its interac-
tion with NFATc2.
 
IRF4 Synergizes with c-maf and NFATc2 to Enhance IL-4
Production.
 
We wished to examine the effect of IRF4 and
NFATc2 on endogenous IL-4 gene expression. Therefore,
we attempted to reconstitute IL-4 gene expression in an es-
tablished M12 B cell system. Although M12 cells do not
normally express IL-4, we have demonstrated previously
that coexpression of the Th2-specific transcription factor,
c-maf, NFATc2, and the NFAT-interacting protein,
NIP45 leads to the induction of endogenous IL-4 produc-
tion in M12 cells (13). Our data suggested that IRF4 con-
tributes to IL-4 induction through its interaction with
NFATc2, and so we sought to examine whether IRF4
would function in combination with NFATc2 and c-maf
to modulate endogenous IL-4 production in this system.
Consistent with previously reported results, c-maf by it-
self induced IL-4 promoter activity in M12 B cells by
 
 
 
100-fold over baseline controls (Fig. 4 a). c-maf and
NFATc2 together augmented IL-4 promoter activity and
also induced detectable levels (100 pg/ml) of endogenous
IL-4 in M12 B cells (Fig. 4, a and b). Coexpression of
IRF4 and NFATc2 increased IL-4 activity by 
 
 
 
300-fold
compared with controls. Interestingly, IRF4 potently syn-
ergized with both NFATc2 and c-maf to greatly enhance
IL-4 transcriptional activity by 
 
 
 
900-fold above baseline
(Fig. 4 a). Importantly, this synergy at the IL-4 promoter
was accompanied by the induction of substantial levels (700
pg/ml) of endogenous IL-4 production in M12 B cells
(Fig. 4 b).
 
Compromised Th2 Differentiation in IRF4
 
 
 
/
 
 
 
 Naïve T
Helper Cells.
 
It has been shown previously that IRF4
 
 
 
/
 
 
 
T cells display reduced proliferation and overall cytokine
production in response to stimulation compared with wild-
type cells. To ascertain whether IL-4 expression requires
Figure 2. Physical association between NFAT and IRF4
does not extend to IRF8. Coimmunoprecipitation of IRF4
and NFATc2. (a) 293T cells were transiently transfected with
Flag-NFATc2 and HA-IRF4 or control vector and immu-
noprecipitated using anti-HA or control anti-myc antibodies.
Proteins were run on SDS-PAGE and immunoblotted with anti-Flag antibody to detect Flag-NFATc2 in the immunoprecipitate and lysates (lys) (b) 293T
cells were transiently transfected with HA-IRF4 and Flag-NFATc2 or control vector. Immunoprecipitation was performed using anti-Flag or control anti-myc
antibodies and immunoblotted with anti-HA antibody to detect HA-IRF4 in the immunoprecipitate or lysate (lys). (c) Extracts from Th1 or Th2 cells
were immunoprecipitated with preimmune serum (P) or anti-NFATc2 antibody and probed with anti-IRF4-HRP or reprobed with anti-NFATc2. (d)
M12 cells were transiently transfected with Flag-NFATc2 and HA-IRF4 or HA-IRF8. Immunoprecipitation with anti-HA antibody and immunoblotting
with anti-Flag antibody to detect immunoprecipitate. Anti-HA antibody was used to immunoblot input lysates to detect IRF4 and IRF8. (e) Comparison
of IRF4 and IRF8 transcriptional synergy with NFATc2 in M12 cells. Results represent the mean of three to five independent experiments. Luciferase ac-
tivity is reported as a fold increase relative to reporter alone  SEM. Control plasmid DNA was used to normalize for DNA concentration. 
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the presence of IRF4, we assessed the ability of naïve T
helper precursors (Thp) from IRF4
 
 
 
/
 
 
 
 mice to differentiate
into cytokine-producing Th1 and Th2 effector subsets in
vitro. Naïve Thp were isolated from wild-type or IRF4
 
 
 
/
 
 
 
lymph nodes and spleens by FACS (see Materials and
Methods) and stimulated with anti-CD3 and anti-CD28
under unskewed conditions (U) and conditions that would
skew them to differentiate into Th1- or Th2-polarized
cells. On day 7 after primary stimulation, the percentage of
U, Th1, and Th2 cells that secreted IL-4 and IFN-
 
 
 
 were
determined by intracellular cytokine staining (Fig. 5 a).
Under unskewed conditions, both wild-type and IRF4
 
 
 
/
 
 
 
cells produced little IL-4, whereas 51% of IRF4
 
 
 
/
 
 
 
 cells se-
creted IFN-
 
 
 
 compared with 30% in the wild type. Under
Th1 conditions, both genotypes showed increased IFN-
 
 
 
,
although the percent increase in cells secreting IFN-
 
 
 
 rela-
tive to unskewed cultures was greater for wild type (30–
80%) compared with IRF4
 
 
 
/
 
 
 
 (51–69%; Fig. 5 a). Impor-
tantly, whereas wild-type cells were able to differentiate
into Th2 cells secreting IL-4 (31%) and negligible IFN- ,
IRF4 / -deficient cells were unable to develop into the
Th2 subset even when provided with exogenous IL-4, as
evidenced by the very small number (4%) of cells produc-
ing IL-4 (Fig. 5 a).
To more closely analyze the inability of IRF4 /  Th
cells to develop into the Th2 subset, cells from each geno-
type and condition also were restimulated with anti-CD3
and the supernatants were analyzed for Th1- (IL-2 and
IFN- ) and Th2 (IL-4, IL-5, and IL-13)-cytokine produc-
tion (Fig. 5 b). The levels of IFN-  produced by wild-type
and IRF4 /  Th cells under U, Th1, and Th2 conditions
paralleled that of the results from intracellular cytokine
staining (Fig. 5 b). IL-2 production by IRF4-deficient cells
was somewhat diminished relative to wild type under all
Figure 3. Mapping the domains of IRF4 required for interaction and tran-
scriptional synergy with NFATc2. (a) 293T cells were transiently transfected
with Flag-NFATc2 and with each of the different HA-IRF4 mutants. Immu-
noprecipitation was performed using anti-HA antibody, and the immunopre-
cipitates were run on SDS-PAGE and detected by immunoblot using anti-
Flag antibody to detect the association of each IRF4 mutant with NFATc2
relative to full-length IRF4 (1–450). Lysates from each transfection also were
run on SDS-PAGE to detect the IRF4 proteins in the input. (b) M12 B lym-
phoma cells were transiently transfected with the IL-4 luciferase reporter and
cotransfected with NFATc2 and each of the different IRF4 mutant expression
plasmids including full-length (1–450). Results represent the mean of five in-
dependent experiments. Luciferase activity is reported as a fold increase rela-
tive to reporter alone  SEM. Control plasmid DNA was used to normalize
for DNA concentration.1009 Rengarajan et al.
three conditions. Strikingly, naïve Thp from IRF4 /  mice
were severely deficient in producing IL-4, IL-5, and IL-13
under Th2-differentiating conditions that included exoge-
nous IL-4 (Fig. 5 b). Thus, naïve Thp from IRF4 /  mice
are unable to differentiate into Th2 cells, but retain the
ability to secrete substantial levels of IFN-  and IL-2.
Discussion
We have identified IRF4, an immune system–restricted
member of the IRF family of transcription factors, as a
partner for NFATc2. Whereas IRF4 is known to activate
the transcription of genes expressed in B cells via its inter-
action with transcription factor protein partners, no such
partner has been described in T cells until this report. The
striking ability of IRF4 to enhance NFAT-driven IL-4
transcriptional activity (Fig. 1, a and b) is consistent with
the known function of IRF4 in transcriptional synergy.
The functional synergy between NFATc2 and IRF4 is not
generalizable to other NFAT-regulated promoters of genes
such as IL-2 and Egr3 (Fig. 1, c and d). The role of IRF4 in
IL-4 production is underscored by the inability of IRF4-
deficient Th cells to differentiate into Th2 cells. Thus,
IRF4 constitutes a new protein partner with which
NFATc2 interacts to regulate context-specific gene tran-
scription. Interestingly, the closely related family member,
IRF8, neither synergizes nor interacts with NFATc2, con-
ferring some specificity to the NFATc2-IRF4 association
(Fig. 2, c and d).
What Might Be the Reasons for Differential Involvement of
IRF4 and IRF8 with NFATc2? Although IRF4 and IRF8
show significant homology (80% identity) in their NH2-
terminal domains, particularly in the conserved IRF DNA
binding domains, they are only 48% homologous over a
160–amino acid region of the IRF4 protein (254–413).
Thus, the interaction surfaces required for protein–protein
contact with NFATc2 may not exist in IRF8. Unlike
IRF4, IRF8 does not appear to possess an activation do-
main (19). Therefore, while it complexes with PU.1 on  B
DNA, it does not augment transcription of the  B reporter
(19). Moreover, IRF8 is important in regulating IL-12 ex-
pression in macrophages and, thus, may not be involved in
IL-4 gene regulation (26, 27).
The NFATc2-IRF4 Interaction. The interaction be-
tween IRF4 and PU.1 has been well characterized at the
molecular level. Many of the functional correlates of IRF4
protein structure have been elucidated with respect to the
ternary complex formed between IRF4, PU.1, and DNA.
The IRF4 protein (full-length 1–450) possesses an NH2-
terminal (1–134) DNA binding domain with high se-
quence homology to other IRF proteins, followed by a
region termed the activation domain that includes a pro-
line-rich segment. The COOH-terminal contains the reg-
ulatory domain (15, 19). Residues 150–340 are important
for ternary complex formation. Amino acids 410–439 are
necessary for complex formation as well autoinhibition of
IRF4 binding to DNA (19). A predicted  -helical structure
(399–413) was shown to be critical for interaction as well as
transcriptional synergy with PU.1 (20). The interaction of
IRF4 with NFATc2 shows some parallels but also some
differences compared with that of PU.1. Like PU.1, the
COOH-terminal residues 410–450, particularly amino ac-
ids 410–439, appear to be required for interaction with
NFATc2 and transcriptional synergy (Fig. 3, a and b). In
addition, deleting residues 399–413 (  H), which comprise
the putative  -helix, eliminates both interaction of IRF4
with NFATc2 and synergistic activation of the IL-4 pro-
moter. Residues 150–340 also appear to be important for
association and synergy with NFATc2 (Fig. 3, a and b).
The interaction of PU.1 and IRF4 has been shown to be
dependent on DNA for the formation of a stable ternary
complex (20). Our results indicate that DNA was not nec-
essary for NFATc2 and IRF4 to interact as we were able to
coimmunoprecipitate NFATc2 and IRF4 when transiently
coexpressed in cell lines (Fig. 3, a and b), as well as within
primary Th1 and Th2 cells. Furthermore, using recombi-
nant or in vitro-translated NFATc2 and IRF4 proteins in
EMSAs with regions of the IL-4 promoter containing
Figure 4. IRF4 synergizes with
NFATc2 and c-maf to enhance IL-4
transcriptional activity and endoge-
nous IL-4 production. M12 cells
were transiently transfected with the
indicated expression plasmids along
with IL-4 luciferase reporter. (a) Af-
ter transfection, half of the trans-
fected cells were cultured for 24 h
and assayed for luciferase activity. (b)
Cells from the other half were cul-
tured for 72 h, and the supernatants
were assayed for IL-4. Results are
representatives of five independent
experiments. Luciferase activity is
reported as a fold increase relative to
reporter alone  SEM. IL-4 was
quantified by ELISA.1010 IRF4 Modulates NFATc2-driven IL-4 Gene Expression
NFAT sites and putative IRF recognition sequences, we
were unable to detect enhanced binding of NFATc2 to
DNA, nor the formation of a ternary complex (unpub-
lished data). Notably, the interaction between IRF4 and
E2A also does not manifest in a ternary complex, although
IRF4 augments the binding of E2A to DNA. We suggest
two possible ways in which NFATc2 and IRF4 may asso-
ciate with one another. The first invokes the formation of a
ternary complex at the IL-4 promoter. IRF4 may cobind
with NFAT to a novel composite element. The functional
synergy between IRF4 and NFATc2 displays some speci-
ficity for the IL-4 promoter (Fig. 1, c and d) and the con-
sensus NFAT site alone (Fig. 1 e) is not sufficient for IRF4
to enhance NFATc2-mediated induction of IL-4 promoter
activity. These data suggest that an IRF4–NFATc2 com-
plex may form but dissociate under conditions used for gel
electrophoresis. IRF4 is known to possess very weak affin-
ity for DNA and, thus, the in vitro conditions of the
EMSAs may not reconstitute the in vivo conditions in which
IRF4 may be able to bind DNA in conjunction with
NFATc2. Moreover, additional proteins may be required
for IRF4 and NFATc2 to associate on DNA. Alternatively,
IRF4 may be tethered to the IL-4 promoter through pro-
tein–protein contacts with NFATc2. Additional proteins,
specific to the IL-4 promoter, may be necessary to maintain
this association. Thus, such interactions would confer spec-
ificity to the ability of IRF4 to modulate NFAT-driven
gene expression. The Th2-specific protein c-maf, with
Figure 5. Compromised Th2 dif-
ferentiation in IRF4 /  naïve Th
cells. Naïve Thp were isolated from
wild-type and IRF4 /  mice and
differentiated in vitro under un-
skewed (U) Th1 or Th2 conditions
(see Materials and Methods). (a) In-
tracellular cytokine staining for IL-4
and IFN-  production on day 7
upon stimulation with PMA and
ionomycin. Percentage of cells that
secrete each cytokine is indicated. (b)
On day 7, U, Th1, and Th2 cells
from wild-type (WT) and IRF4 / 
mice were stimulated with anti-CD3,
and supernatants were analyzed for
cytokine production 24 h later.1011 Rengarajan et al.
which IRF4 potently synergizes in conjunction with
NFATc2 to induce endogenous IL-4 production (Fig. 4, a
and b), may play a role in facilitating the interactions pro-
posed in this model. The critical function for IRF4 in Th2-
cytokine production that we have demonstrated in IRF4-
deficient mice supports a role for IRF4 in modulating
NFAT-dependent pathways via protein–protein interac-
tion with NFATc2 in vivo.
IRF4 and T Helper Cell Function. The specific interac-
tion between NFATc2 and IRF4 within primary Th1 and
Th2 cells (Fig. 2 c) suggests that the association of these
two proteins within Th cells plays a role in regulating Th
cell function. Previous studies indicated that IRF4-defi-
cient T cells showed reduced proliferation and cytokine
production (22). In this report, we specifically examined
naïve Th precursor cells from IRF4 /  mice and observed
a slight reduction in IFN-  and IL-2 production, which
may reflect decreased proliferative capacity relative to wild
type. Importantly, IRF4 /  mice are compromised se-
verely for the production of IL-4, IL-5, and IL-13 and are
unable to differentiate into Th2 cells (Fig. 5). This pro-
found reduction in Th2 cytokine production, even with
the provision of exogenous IL-4, cannot be fully explained
by the modest reduction in IL-2 production (Fig. 5 b).
Thus, these data imply that the presence of IRF4 is neces-
sary for IL-4 production and for generating the Th2 com-
partment. What might be the mechanism for the regulation
of IL-4 by IRF4? IRF4 mRNA is expressed equally in
Th1- and Th2-polarized subsets (unpublished data) and
IRF4–NFATc2 protein complexes were equally present in
both subsets (Fig. 2 c). However, the specific protein com-
plexes in which NFATc2 and IRF4 participate may be dif-
ferent in the Th1 versus the Th2 context. There is evi-
dence that the chromatin conformation at the IL-4 locus is
different between Th1 and Th2 cells (28). Moreover, both
NFATc2 and the Th2-specific transcription factor GATA3
have been shown to bind to a CsA-sensitive enhancer re-
gion at the IL-4 gene locus in Th2, but not in Th1, cells
(7). IRF4 may be a component of such a Th2-specific pro-
tein complex and serve to enhance the function of
NFATc2 via its physical interaction with NFATc2 at the
IL-4 locus. Indeed, the production of other Th2 cytokines
such as IL-5 and IL-13 also was severely abrogated in
IRF4 /  mice. Genes encoding IL-4, IL-5 and IL-13 are
clustered in the genome, suggesting their coordinate regu-
lation. Thus, IRF4 may influence the expression of the IL-
4/IL-5/IL-13 locus through protein–protein contact with
NFATc2.
The interplay between NFATc2 and IRF4 may extend
to additional aspects of NFAT function in T cells. We have
observed, similar to recently published results, that the in-
duction of IRF4 mRNA is CsA-sensitive (unpublished
data; 29). We have evidence that IRF4 may be induced, in
part, by NFATc2 since Th cells from mice doubly deficient
in NFATc2 and NFATc3 exhibit reduced IRF4 mRNA
induction (unpublished data). Thus, it is intriguing to con-
sider that NFATs may induce as well as interact with IRF4
in regulating target gene expression.
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